Related Experiment Videos
Mid-term results of autoinjection therapy for erectile dysfunction
1Department of Urology, Academic Hospital, University of Ulm, West Germany.
Urology
|June 1, 1988
Summary
Intracavernosal autoinjection therapy using papaverine-phentolamine is effective for erectile dysfunction. Patients required a lower dose at home, with minimal side effects like prolonged erections, which were easily managed.
Area of Science:
- Urology
- Andrology
- Pharmacology
Background:
- Erectile dysfunction (ED) affects a significant number of men.
- Intracavernosal autoinjection therapy (ICAT) is a treatment option for ED.
- Standardized medication mixtures are used to optimize ICAT efficacy and safety.
Purpose of the Study:
- To evaluate the efficacy and safety of a standardized papaverine-phentolamine mixture for ICAT in patients with ED.
- To determine dose requirements for ICAT in a home setting compared to hospital administration.
- To assess the incidence and management of local and systemic side effects associated with ICAT.
Main Methods:
- A cohort of 186 patients with ED were selected for ICAT using a papaverine-phentolamine mixture.
- 156 patients completed 4,813 autoinjections, with a mean of 31 injections per patient.
- Dose adjustments and side effect profiles were monitored during diagnostic and therapeutic use.
Main Results:
- A mean dose reduction of 35% was observed when patients self-administered injections at home compared to hospital settings.
- No systemic side effects were reported.
- Prolonged erections occurred in 24 patients during diagnostic use and 3 patients during therapeutic use, all managed without lasting consequences.
Conclusions:
- Standardized papaverine-phentolamine ICAT is an effective treatment for erectile dysfunction.
- Home self-administration allows for significant dose reduction while maintaining efficacy.
- The therapy is generally safe, with manageable local side effects.